Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity.

Walti, Laura Naëmi; Steinrücken, Julia; Rauch, Andri; Wandeler, Gilles (2018). Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity. Open Forum Infectious Diseases, 5(11), ofy275. Oxford University Press 10.1093/ofid/ofy275

[img]
Preview
Text
Walti_TAFearlyaccess_OFID18.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (300kB) | Preview

Although the use of tenofovir alafenamide (TAF), a new prodrug of tenofovir, was safe and efficacious in clinical trials, real-world data from multimorbid individuals are scarce. Among 10 persons living with HIV with previous tenofovir disoproxil fumarate-induced nephrotoxicity, renal function remained stable, and proteinuria decreased in several patients after the switch to TAF.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Walti, Laura Naëmi; Steinrücken, Julia; Rauch, Andri and Wandeler, Gilles

Subjects:

300 Social sciences, sociology & anthropology > 360 Social problems & social services
600 Technology > 610 Medicine & health

ISSN:

2328-8957

Publisher:

Oxford University Press

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

13 Dec 2018 13:23

Last Modified:

18 Dec 2018 09:29

Publisher DOI:

10.1093/ofid/ofy275

PubMed ID:

30515426

Uncontrolled Keywords:

antiretroviral therapy chronic kidney disease drug nephrotoxicity tenofovir alafenamide

BORIS DOI:

10.7892/boris.122369

URI:

https://boris.unibe.ch/id/eprint/122369

Actions (login required)

Edit item Edit item
Provide Feedback